PureTech’s Deupirfenidone (LYT-100) Demonstrates Superior Efficacy in Slowing Lung Function Decline in Idiopathic Pulmonary Fibrosis (IPF) Phase 2b Trial
Efficacy:
Deupirfenidone (LYT-100) showed an 80.9% treatment effect versus placebo in slowing lung function decline, significantly outperforming pirfenidone's 54.1% effect14.
Trial Design:
The ELEVATE IPF Phase 2b trial was a randomized, double-blind study that evaluated deupirfenidone at doses of 550 mg and 825 mg TID compared to pirfenidone at the FDA-approved dose14.
Primary Endpoint:
The trial achieved its primary endpoint, demonstrating that deupirfenidone was superior to placebo in slowing lung function decline as measured by forced vital capacity (FVC) at 26 weeks14.
Tolerability:
Both doses of deupirfenidone showed favorable tolerability with comparable gastrointestinal adverse events to pirfenidone14.
Future Development:
The results support the continued development of deupirfenidone as a potential new standard of care for IPF, with over 90% of trial completers opting to enroll in the ongoing open-label extension study14.
Sources:
1. https://www.stocktitan.net/news/PRTC/pure-tech-s-deupirfenidone-lyt-100-slowed-lung-function-decline-in-spoacslaqbxm.html
4. https://www.clinicaltrialsarena.com/news/puretech-sees-success-in-phase-iib-pulmonary-fibrosis-trial/